Nouhad Husseini
Director/Miembro de la Junta en DECIBEL THERAPEUTICS, INC. .
Cargos activos de Nouhad Husseini
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2011 | - |
| CHECKMATE PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 31/05/2022 | - |
| Corporate Officer/Principal | 31/05/2022 | - | |
| DECIBEL THERAPEUTICS, INC. | Director/Miembro de la Junta | 22/09/2023 | - |
| Corporate Officer/Principal | 22/09/2023 | - |
Historial de carrera de Nouhad Husseini
Formación de Nouhad Husseini.
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Nouhad Husseini
- Experiencia
